[HTML][HTML] The resistance to EGFR-TKIs in non-small cell lung cancer: from molecular mechanisms to clinical application of new therapeutic strategies
C Laface, FM Maselli, AN Santoro, ML Iaia, F Ambrogio… - Pharmaceutics, 2023 - mdpi.com
Almost 17% of Western patients affected by non-small cell lung cancer (NSCLC) have an
activating epidermal growth factor receptor (EGFR) gene mutation. Del19 and L858R are the …
activating epidermal growth factor receptor (EGFR) gene mutation. Del19 and L858R are the …
The Resistance to EGFR-TKIs in Non-Small Cell Lung Cancer: From Molecular Mechanisms to Clinical Application of New Therapeutic Strategies
C Laface, FM Maselli, AN Santoro, ML Iaia… - …, 2023 - search.proquest.com
Almost 17% of Western patients affected by non-small cell lung cancer (NSCLC) have an
activating epidermal growth factor receptor (EGFR) gene mutation. Del19 and L858R are the …
activating epidermal growth factor receptor (EGFR) gene mutation. Del19 and L858R are the …
The Resistance to EGFR-TKIs in Non-Small Cell Lung Cancer: From Molecular Mechanisms to Clinical Application of New Therapeutic Strategies
C Laface, FM Maselli, AN Santoro, ML Iaia… - …, 2023 - pubmed.ncbi.nlm.nih.gov
Almost 17% of Western patients affected by non-small cell lung cancer (NSCLC) have an
activating epidermal growth factor receptor (EGFR) gene mutation. Del19 and L858R are the …
activating epidermal growth factor receptor (EGFR) gene mutation. Del19 and L858R are the …
The Resistance to EGFR-TKIs in Non-Small Cell Lung Cancer: From Molecular Mechanisms to Clinical Application of New Therapeutic Strategies.
C Laface, FM Maselli, AN Santoro, ML Iaia… - …, 2023 - search.ebscohost.com
Almost 17% of Western patients affected by non-small cell lung cancer (NSCLC) have an
activating epidermal growth factor receptor (EGFR) gene mutation. Del19 and L858R are the …
activating epidermal growth factor receptor (EGFR) gene mutation. Del19 and L858R are the …
The Resistance to EGFR-TKIs in Non-Small Cell Lung Cancer: From Molecular Mechanisms to Clinical Application of New Therapeutic Strategies.
C Laface, FM Maselli, AN Santoro, ML Iaia… - …, 2023 - europepmc.org
Almost 17% of Western patients affected by non-small cell lung cancer (NSCLC) have an
activating epidermal growth factor receptor (EGFR) gene mutation. Del19 and L858R are the …
activating epidermal growth factor receptor (EGFR) gene mutation. Del19 and L858R are the …
[HTML][HTML] The Resistance to EGFR-TKIs in Non-Small Cell Lung Cancer: From Molecular Mechanisms to Clinical Application of New Therapeutic Strategies
C Laface, FM Maselli, AN Santoro, ML Iaia… - …, 2023 - ncbi.nlm.nih.gov
Almost 17% of Western patients affected by non-small cell lung cancer (NSCLC) have an
activating epidermal growth factor receptor (EGFR) gene mutation. Del19 and L858R are the …
activating epidermal growth factor receptor (EGFR) gene mutation. Del19 and L858R are the …
The Resistance to EGFR-TKIs in Non-Small Cell Lung Cancer: From Molecular Mechanisms to Clinical Application of New Therapeutic Strategies.
C Laface, FM Maselli, AN Santoro, ML Iaia… - …, 2023 - europepmc.org
Almost 17% of Western patients affected by non-small cell lung cancer (NSCLC) have an
activating epidermal growth factor receptor (EGFR) gene mutation. Del19 and L858R are the …
activating epidermal growth factor receptor (EGFR) gene mutation. Del19 and L858R are the …